Table 2.
Mutations in CD19+, CD34+CD19−, CD3+ and CD14+ PB cell populations identified by ultra-deep NGS
| Time point 1; bone narrow | Time point 2: peripheral blood | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Patient ID | IGHV mutation status | Mutated gene | AA change | %mut CD19 | %mut CD34 | %mut CD19+ | %mut CD34+CD19− | %mut CD3+ | %mut CD14+ |
| 13 | Mutated | MYD88 | p.M232T | 36 | 22 | 23.1 | 12.2 | 2.6 | 7.7 |
| 31 | Mutated | NOTCH1 | p.P2514Rfs*4 | 4 | < 10 | 15.3 | 2.1 | 0 | 0 |
| 36 | Mutated | FBXW7 | p.R465L | 39 | < 10 | 3.2 | 3.0 | 2.7 | 3.6 |
| 37 | Unmutated | XPO1 | p.E571K | 51 | 38 | 53.0 | 3.0 | 3.0 | 0.4 |
| 42 | Unmutated | NOTCH1 | p.P2514Rfs*4 | 5.25 | < 10 | 33.0 | 12.9 | 0 | 0.6 |
| 50 | Unmutated | SF3B1 | p.R625H | 21 | < 10 | 15.0 | 1.0 | 0.1 | 0.1 |
| 50 | Unmutated | FBXW7 | p.G423V | 8 | < 10 | 0 | 0 | 0 | 0 |
| 57 | Mutated | FBXW7 | p.R465H | 42 | 13 | 46.5 | 2.4 | 0.8 | 2.6 |
The cut-off set for the second time point was 2% (bold) provided that our FACS purities were higher than 98% in all cases for all cell populations